4 entries found
Sort by: Latest |Relevance
27 Sep 2012 description
report The Global Fund

EXECUTIVE SUMMARY

KEY RESULTS INCLUDE:

3.6 million people currently receiving antiretroviral therapy

9.3 million people treated for tuberculosis

270 million insecticide-treated nets distributed to protect families from malaria

8.7 million lives saved

27 May 2010 description

Joint press release

NAIROBI, KENYA, 27, May 2010 - Government representatives from 20 African countries highly affected by HIV/AIDS gathered today in Nairobi to discuss ways to virtually eliminate mother-to-child transmission of HIV by 2015.

The three-day-consultation from 26 to 28 May is co-organized by the Global Fund to fight AIDS, Tuberculosis and Malaria and UN agencies, including UNAIDS, UNICEF, UNFPA and WHO. Participants are exploring how to expand and strengthen services for pregnant women and increase treatment for infected mothers and children.

08 Jul 2009 description
report The Global Fund

88 Million Bed Nets Distributed for Malaria

Geneva - The Global Fund to Fight AIDS, Tuberculosis and Malaria today announced that 2.3 million people living with HIV have been reached with lifesaving antiretroviral (ARV) treatment through AIDS programs it supports, a 31 per cent increase over results reported a year ago.

Global Fund-supported tuberculosis programs have so far put more than 5.4 million people on effective TB drugs treatment. Tuberculosis is the leading cause of death among HIV-infected people; the World Health Organization estimates that TB accounts for up to a …

01 Jun 2009 description
report The Global Fund


This fact sheet outlines the principles and approach in determining the number of people on antiretroviral drugs (ARVs) for HIV/AIDS treatment, with a breakdown of the results by country, and answers to commonly-asked questions.

Question 1: How many people are receiving ARVs from programs supported by Global Fund grants?

As of June 1st 2009, programs supported by the Global Fund have reported 2.3 million people currently on ARVs for treatment of HIV/AIDS.

Question 2: What is the regional breakdown of people currently receiving ARVs?